Natixis Advisors LLC Buys 11,177 Shares of ICON Public Limited (NASDAQ:ICLR)

Natixis Advisors LLC raised its stake in shares of ICON Public Limited (NASDAQ:ICLR) by 6.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 177,761 shares of the medical research company’s stock after purchasing an additional 11,177 shares during the period. Natixis Advisors LLC owned 0.22% of ICON Public worth $37,279,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ICLR. Icon Wealth Advisors LLC lifted its position in shares of ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after acquiring an additional 11,840 shares in the last quarter. Foyston Gordon & Payne Inc purchased a new position in shares of ICON Public in the third quarter valued at about $11,672,000. Tributary Capital Management LLC lifted its position in shares of ICON Public by 116.1% in the fourth quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock valued at $828,000 after acquiring an additional 2,122 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares in the last quarter. Finally, Entropy Technologies LP lifted its position in shares of ICON Public by 472.2% in the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock valued at $1,295,000 after acquiring an additional 5,095 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ICLR shares. Truist Financial lowered their price objective on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Robert W. Baird decreased their target price on ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a research report on Wednesday, January 15th. JPMorgan Chase & Co. decreased their target price on ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Finally, Leerink Partners reiterated an “outperform” rating and issued a $255.00 target price (down from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, ICON Public presently has an average rating of “Moderate Buy” and a consensus price target of $279.17.

ICON Public Trading Up 3.1 %

Shares of NASDAQ ICLR opened at $184.58 on Monday. The business’s 50 day moving average is $196.16 and its two-hundred day moving average is $230.38. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. ICON Public Limited has a 1-year low of $174.93 and a 1-year high of $347.72. The stock has a market capitalization of $14.91 billion, a P/E ratio of 19.37, a PEG ratio of 1.86 and a beta of 1.21.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.01. The firm had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. As a group, research analysts expect that ICON Public Limited will post 13.38 EPS for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.